USANA Issues Preliminary 2022 Results Above Guidance and Initial 2023 Outlook

SALT LAKE CITY, January 5, 2023 -- USANA Health Sciences said it anticipates fiscal 2022 net sales of about 995 million dollars and diluted earnings per share of about 3.65 dollars, above its most recent guidance of 955 million to 975 million dollars in sales and 3.15 to 3.40 dollars in diluted EPS. Year-end active customers were about 490,000.

The company said fourth-quarter and full-year sales benefited from incremental mainland China demand in the final two weeks after a shift in COVID policy, though it lacked visibility into how long that demand would continue. Chief executive Kevin Guest said active customer counts stabilized in the fourth quarter as Asia Pacific lockdowns eased.

USANA issued initial fiscal 2023 guidance of 850 million to 950 million dollars in net sales and 2.35 to 3.30 dollars in diluted EPS, citing a lower starting customer base, Asia Pacific uncertainty, an estimated 30 million dollar currency headwind and more normalized promotions.